Malpeli Giorgio, Barbi Stefano, Moore Patrick S, Scardoni Maria, Chilosi Marco, Scarpa Aldo, Menestrina Fabio
Dipartimento di Patologia, Sezione di Anatomia Patologica Università di Verona, Strada Le Grazie I-37134 Verona, Italy.
Haematologica. 2004 Sep;89(9):1091-9.
Somatic hypermutation of the BCL6 gene and its expression in lymphoma represent specific markers for B-cell transit through the germinal center. Thus, analysis of BCL6 may aid in clarifying the relationship between primary mediastinal B-cell lymphoma (PMBL) and other non-thymic diffuse large cell lymphomas (DLCL).
Twenty-four PMBL were analyzed for BCL6 status, including first intron mutations, by quantitative reverse transcription polymerase chain reaction (RT-PCR), and immunohistochemistry. We also performed a meta-analysis of reported BCL6 mutations in PMBL (n=141), DLCL (n=233), and follicular lymphoma (n=120).
Thirteen PMBL (54%) showed hypermutation of BCL6. All cases showed bcl6 mRNA and immunohistochemical expression. Meta-analysis demonstrated that the preferentially altered sequence motifs of BCL6 in PMBL were TA (p=0.002) and AT (p=0.0008) dinucleotides and TAT trinucleotides (p=0.001). GC and RGYW/WRCY motifs were a target in DLCL and FL but not in PMBL. Moreover, the DNA stretch spanning nucleotides 150-270 was highly targeted only in PMBL.
The consistent expression of bcl6 protein and occurrence of hypermutation indicate that PMBL should be considered of germinal center origin. The fact that the hypermutation sites and mutational spectrum of BCL6 in PMBL differ from those found in FL and DLCL might suggest that the maturation block of the transforming cells differs among these tumor types, and that the characteristic mutational pattern is present before neoplastic transformation. Thus, our findings strengthen the hypothesis that PMBL originate from an already defined sub-population of B-cells, which are different from those leading to either DLCL or FL.
BCL6基因的体细胞超突变及其在淋巴瘤中的表达代表了B细胞穿越生发中心的特异性标志物。因此,对BCL6的分析可能有助于阐明原发性纵隔B细胞淋巴瘤(PMBL)与其他非胸腺弥漫大B细胞淋巴瘤(DLCL)之间的关系。
通过定量逆转录聚合酶链反应(RT-PCR)和免疫组织化学分析了24例PMBL的BCL6状态,包括第一内含子突变。我们还对已报道的PMBL(n = 141)、DLCL(n = 233)和滤泡性淋巴瘤(n = 120)中的BCL6突变进行了荟萃分析。
13例PMBL(54%)显示BCL6超突变。所有病例均显示bcl6 mRNA和免疫组化表达。荟萃分析表明,PMBL中BCL6优先改变的序列基序是TA(p = 0.002)和AT(p = 0.0008)二核苷酸以及TAT三核苷酸(p = 0.001)。GC和RGYW/WRCY基序是DLCL和FL中的靶点,但在PMBL中不是。此外,仅在PMBL中,跨越核苷酸150 - 270的DNA片段是高度靶向的。
bcl6蛋白的一致表达和超突变的发生表明PMBL应被认为起源于生发中心。PMBL中BCL6的超突变位点和突变谱与FL和DLCL中发现的不同这一事实可能表明,这些肿瘤类型中转化细胞的成熟阻滞不同,并且特征性突变模式在肿瘤转化之前就已存在。因此,我们的发现强化了PMBL起源于已定义的B细胞亚群的假设,这些B细胞与导致DLCL或FL的B细胞不同。